IP Library › Granted Patent US 12,629,351
Granted Patent B2
US 12,629,351 · App. 18/044,024 · Granted May 19, 2026

HDAC inhibitors for idiopathic pulmonary fibrosis and other lung inflammatory disorders

Inventors: Srivari Chandrasekhar (Telangana, IN); Prathama S Mainkar (Telangana, IN); Chada Raji Reddy (Telangana, IN); Sistla Ramakrishna (Telangana, IN); Andugulapati Sai Balagi (Telangana, IN); Kuncha Madhusudana (Telangana, IN); Muppidi Mohan Venkata Subbarao (Telangana, IN); Tirunavalli Satya Krishna (Telangana, IN)
Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860))
A61K31/404A61K31/4439A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,629,351
App. No.
18/044,024
Granted
May 19, 2026
Kind
B2
Abstract

The present invention relates to compound of Formula 1 for use in treating IPF, by reducing collagen deposition in lungs, attenuating the fibrotic marker's expression (in IPF cell-lines Bleomycin induced rat lungs) and improving the bleomycin induced pathological changes in rat lungs, and ARDS, by reducing the cytokine storm. The invention also relates to compound of Formula 1 for use in treating various fibrotic disorders like lung injuries caused by virus or bacterial infections, cardiac, hepatic and kidney fibrosis.

Claims (16)

1 . A method of treating a condition selected from lung inflammatory disorders, and fibrotic disorders, wherein the method comprises administering to a patient in need of such treatment a therapeutically effective amount of sulfonyl hydroxamine acid compound of formula 1

wherein

Ring A and B are independently selected from aryl, heteroaryl, cycloalkyl, fused aryl, or fused alkyl group;

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently selected from hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, nitro, cyano, and aldehyde; and X is O; and

wherein the sulfonyl hydroxamine acid compound of formula 1 selectively inhibit HDAC-6 and/or HDAC-8.

2 . The method of claim 1 , wherein the compound is:

3 . The method of claim 1 , wherein the lung inflammatory disorders related to cytokine storm comprise Acute lung injury, Acute respiratory distress syndrome (ARDS), or Idiopathic pulmonary fibrosis, or wherein the fibrotic disorders comprise hepatic fibrosis, cardiac fibrosis, or kidney fibrosis.

4 . The method of claim 1 , further comprising attenuating the lipopolysaccharides (LPS) induced infiltration of WBC and Neutrophils.

5 . The method of claim 1 , further comprising attenuating the LPS induced Lung volume (index), and spleen Indices.

6 . The method of claim 1 , further comprising reducing the expression of inflammatory markers consisting of pro-inflammatory cytokines (IL-6, IL-1β or IL-8), chemokines (CCL2 or CCL-7) or chemokine ligands (CXCL-6, CXCL-10 or CXCL-11), and TLR3 genes.

7 . The method of claim 1 , further comprising attenuating the LPS induced IL-6 levels in plasma samples.

8 . The method of claim 1 , further comprising attenuating the extra cellular matrix proteins, collagen, and epithelial to mesenchymal markers expression in TGF-β stimulated LL29, DHLF, or NHLF cells.

9 . The method of claim 1 , further comprising mitigating the inflammatory markers expression and infiltration of neutrophils in BLM challenged rats.

10 . The method of claim 1 , further comprising reducing the lung index and hydroxyproline levels in BLM challenged rats.

11 . The method of claim 1 , further comprising attenuating the fibrotic markers expression in BLM challenged rats.

12 . The method of claim 1 , wherein the effective dose ranges between 2 mg/kg to 4 mg/kg body weight.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2024
From: CHANDRASEKHAR, SRIVARI; S MAINKAR, PRATHAMA; RAJI REDDY, CHADA; RAMAKRISHNA, SISTLA; SAI BALAGI, ANDUGULAPATI; MADHUSUDANA, KUNCHA; MOHAN VENKATA SUBBARAO, MUPPIDI; SATYA KRISHNA, TIRUNAVALLI
To: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)
Reel/Frame 067004/0728 →
Priority Claims (1)
IN 202011038497 · Sep 5, 2020 · national
Continuity (1)
Related Publication 20230321038A1 · Oct 12, 2023
References Cited (34)
US 7368572B2 · Sendzik · 2008 [cited by applicant]
WO WO2008068170 · 2008 [cited by applicant]
WO WO2019102488A1 · 2019 [cited by applicant]
Lyu et al., Ther Adv Chronic Dis, Jan. 2019, vol. 10: 1-19 (Year: 2019). [cited by examiner]
Belikov, “Pharmaceutical Chemistry: Training Manual (4th Edition),” Moscow MEDpress-inform, 2007, pp. 27-29 (with Machine translation). [cited by applicant]
Extended European Search Report in European Appln. No. 21863852.6, mailed on Aug. 7, 2024, 10 pages. [cited by applicant]
Joshi et al., “Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function,” American Journal of Physiology—Lung Cellular and Molecul… [cited by applicant]
Kholodov et al., “Clinical Pharmacokinetics,” Moscow Medicine, 1985, pp. 83-98, 134-138, and 378-380 (with Machine translation). [cited by applicant]
Leus et al., “HDAC 3-selective inhibitor RGFP66 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NFKB p65 transcriptional activity,” Biochemical Pharm… [cited by applicant]
Liu et al., “HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury,” Toxicology and Applied Pharmacology, Mar. 2019, 370:178-183 (Author Manuscript). [cited by applicant]
Lyu et al., “HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis,” Therapeutic Advances in Chronic Disease, Jan. 2019, 10:1-19. [cited by applicant]
Yoon et al., “HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases,” International Journal of Molecular Sciences, Mar. 2019, 20(6):1329, 15 pages. [cited by applicant]
Akgedik et al., “Effect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats,” Inflammation, Jun. 17, 2012, 35:1732-1741. [cited by applicant]
Ashcroft et al., “Simple method of estimating severity of pulmonary fibrosis on a numerical scale,” J Clin Pathol, 1988, 41:467-470. [cited by applicant]
Balaji et al., “Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems,” Phytomedicine, Nov. 2020, 16 pag… [cited by applicant]
Balaji et al., “Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance,” PloS one, May 12, 2016, 22 pages. [cited by applicant]
Barnes et al., “Anti-inflammatory actions of steroids: molecular mechanisms,” Trends Pharmacol Sci., Dec. 1993, 14:436-441. [cited by applicant]
George et al., “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy,” The Lancet Respir. Med., Aug. 2020, pp. 807-815. [cited by applicant]
Khilnani et al., “Corticosteroids and ARDS: A review of treatment and prevention evidence,” Lung India: official organ of Indian Chest Society, Jun. 2011, 28(2):114-119. [cited by applicant]
Korfei et al., “Comparison of the antifibrotic effects of the pan-histone deacetylase- inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis,” PLoS One, N… [cited by applicant]
Richeldi et al., “Idiopathic pulmonary fibrosis,” The Lancet, Mar. 29, 2017, 389(10082):1941-1952. [cited by applicant]
Roy et al., “Immunologic Therapy for ARDS, Septic Shock, and Multiple-Organ Failure,” Clinical Implications of Basic Research, Mar. 1993, 103(3):932-943. [cited by applicant]
Saito et al., “HDAC8 inhibition ameliorates pulmonary fibrosis,” Am.J of Physiol. Lung cellular molecular physiology, 2019, 316(1):L175-L186. [cited by applicant]
Saito et al., “Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway,” PloS one, Oct. 18, 2017, 17 pages. [cited by applicant]
Shu et al., “Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis,” Progress in retinal and eye research, Sep. 2017, 51 pages. [cited by applicant]
Spagnolo et al., “Pulmonary fibrosis secondary to COVID-19: a call to arms?” The Lancet Respir. Med, Aug. 2020, pp. 750-752. [cited by applicant]
Tang et al., “Histone deacetylases as targets for treatment of multiple diseases,” Clinical science, Jun. 2013, 22 pages. [cited by applicant]
Uckun et al., “Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in COVID-19,” Clin. Invest. (Lond.), May 31, 2020, 10(2):35-44. [cited by applicant]
Wu et al., “Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China,” JAMA Intern Med., Jul. 2020, 180(7):1-11. [cited by applicant]
Zaghloul et al., “Attenuation of Bleomycin-induced pulmonary fibrosis in rats by flavocoxid treatment,” Egypt. J. Basic Appl. Sci., Nov. 2, 2017, pp. 256-263. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/IN2021/050851, mailed on Dec. 6, 2021, 10 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/IN2021/050851, mailed on Mar. 16, 2023, 8 pages. [cited by applicant]
Khabele, “The therapeutic potential of class 1 selective histone deacetylase inhibitors in ovarian cancer,” Frontiers in Oncology, May 2014, 4:111, 8 pages. [cited by applicant]
Schuetze et al., “Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts,” The Journal of Pharmacology and Experimental Therapeutics, Apr. 2017, 361(1):140-150. [cited by applicant]